vs
Side-by-side financial comparison of Hilltop Holdings Inc. (HTH) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
Hilltop Holdings Inc. is the larger business by last-quarter revenue ($300.5M vs $207.8M, roughly 1.4× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 13.0%, a 44.4% gap on every dollar of revenue.
Hilltop Holdings Inc. is a financial holding company based in Dallas, Texas. It offers financial products and banking services through three primary subsidiaries: PlainsCapital Bank, PrimeLending, and HilltopSecurities.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
HTH vs IDYA — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $300.5M | $207.8M |
| Net Profit | $39.0M | $119.2M |
| Gross Margin | — | — |
| Operating Margin | — | 52.2% |
| Net Margin | 13.0% | 57.4% |
| Revenue YoY | — | — |
| Net Profit YoY | -12.4% | 330.1% |
| EPS (diluted) | $0.64 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $300.5M | — | ||
| Q4 25 | $329.9M | — | ||
| Q3 25 | $330.2M | $207.8M | ||
| Q2 25 | $303.3M | — | ||
| Q1 25 | $318.5M | — | ||
| Q4 24 | $301.1M | — | ||
| Q3 24 | $305.5M | $0 | ||
| Q2 24 | $297.0M | $0 |
| Q1 26 | $39.0M | — | ||
| Q4 25 | $41.6M | — | ||
| Q3 25 | $45.8M | $119.2M | ||
| Q2 25 | $36.1M | — | ||
| Q1 25 | $42.1M | — | ||
| Q4 24 | $35.5M | — | ||
| Q3 24 | $29.7M | $-51.8M | ||
| Q2 24 | $20.3M | $-52.8M |
| Q1 26 | — | — | ||
| Q4 25 | 16.1% | — | ||
| Q3 25 | 18.4% | 52.2% | ||
| Q2 25 | 16.3% | — | ||
| Q1 25 | 18.1% | — | ||
| Q4 24 | 14.7% | — | ||
| Q3 24 | 13.9% | — | ||
| Q2 24 | 10.0% | — |
| Q1 26 | 13.0% | — | ||
| Q4 25 | 12.6% | — | ||
| Q3 25 | 13.9% | 57.4% | ||
| Q2 25 | 11.9% | — | ||
| Q1 25 | 13.2% | — | ||
| Q4 24 | 11.8% | — | ||
| Q3 24 | 9.7% | — | ||
| Q2 24 | 6.8% | — |
| Q1 26 | $0.64 | — | ||
| Q4 25 | $0.68 | — | ||
| Q3 25 | $0.74 | $1.33 | ||
| Q2 25 | $0.57 | — | ||
| Q1 25 | $0.65 | — | ||
| Q4 24 | $0.55 | — | ||
| Q3 24 | $0.46 | $-0.60 | ||
| Q2 24 | $0.31 | $-0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $786.9M |
| Total DebtLower is stronger | $990.8M | — |
| Stockholders' EquityBook value | $2.2B | $1.1B |
| Total Assets | $15.7B | $1.2B |
| Debt / EquityLower = less leverage | 0.46× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $786.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $920.0M | ||
| Q2 24 | — | $701.7M |
| Q1 26 | $990.8M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | $1.1B | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.2B | $1.2B | ||
| Q2 24 | $2.1B | $931.7M |
| Q1 26 | $15.7B | — | ||
| Q4 25 | $15.8B | — | ||
| Q3 25 | $15.6B | $1.2B | ||
| Q2 25 | $15.4B | — | ||
| Q1 25 | $15.8B | — | ||
| Q4 24 | $16.3B | — | ||
| Q3 24 | $15.9B | $1.2B | ||
| Q2 24 | $15.6B | $973.7M |
| Q1 26 | 0.46× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $142.2M |
| Free Cash FlowOCF − Capex | — | $142.2M |
| FCF MarginFCF / Revenue | — | 68.4% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-38.7M | — | ||
| Q3 25 | $273.0M | $142.2M | ||
| Q2 25 | $-234.6M | — | ||
| Q1 25 | $5.8M | — | ||
| Q4 24 | $273.9M | — | ||
| Q3 24 | $515.6M | $-49.2M | ||
| Q2 24 | $-435.3M | $-32.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-55.5M | — | ||
| Q3 25 | $271.0M | $142.2M | ||
| Q2 25 | $-234.6M | — | ||
| Q1 25 | $5.0M | — | ||
| Q4 24 | $266.8M | — | ||
| Q3 24 | $513.8M | $-49.7M | ||
| Q2 24 | $-437.3M | $-33.9M |
| Q1 26 | — | — | ||
| Q4 25 | -16.8% | — | ||
| Q3 25 | 82.1% | 68.4% | ||
| Q2 25 | -77.4% | — | ||
| Q1 25 | 1.6% | — | ||
| Q4 24 | 88.6% | — | ||
| Q3 24 | 168.2% | — | ||
| Q2 24 | -147.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 5.1% | — | ||
| Q3 25 | 0.6% | 0.0% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | -0.93× | — | ||
| Q3 25 | 5.96× | 1.19× | ||
| Q2 25 | -6.50× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 7.71× | — | ||
| Q3 24 | 17.36× | — | ||
| Q2 24 | -21.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HTH
| Noninterest Income | $188.4M | 63% |
| Net Interest Income | $112.1M | 37% |
IDYA
Segment breakdown not available.
